Exploratory Study Using Nanotechnology to Detect Biomarkers of Parkinson's Disease From Exhaled Breath

Exploratory Study to Detect Volatile Biomarkers of Idiopathic Parkinson's Disease and Parkinsonism From Exhaled Breath Using a Nanomedical Artificial Olfactory System.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01246336

Enrollment

Registered

2010-11-23

Start date

2009-08-31

Completion date

2012-01-31

Last updated

2017-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinsonism, Parkinson's Disease

Keywords

Parkinson's disease, Parkinsonism, Biomarkers, Exhaled breath, Nanothechnology

Brief summary

Parkinson's disease is diagnosed clinically, because biomarkers that may help in diagnosis and differential diagnosis are not yet available. Exhaled breath testing may yield a breath-print that can be used to distinguish healthy and diseased states.

Interventions

OTHERcollection of exhaled breath

no intervention

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients with Parkinsonism

Exclusion criteria

* Severe dementia

Design outcomes

Primary

Measure	Time frame	Description
Nanosensory detection	immediate	analyze combinations of nanomaterial-based sensors (organically functionalized carbon nanotubes and gold nanoparticles)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026